Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Health claims meeting

This article was originally published in The Tan Sheet

Executive Summary

An FDA public meeting to assess consumer perceptions of health claims will be held Nov. 17 at the Center for Food Safety & Applied Nutrition Harvey Wiley Auditorium from 9 a.m. to 4:30 p.m., the agency announces in a Federal Register notice Oct. 19. The agency will present findings from research assessing consumer reactions to health claims and "address the implications of these studies for future research" evaluating the effect of health claims on consumer behavior. Those who wish to make presentations must register by Nov. 10. Comments also are being collected through Jan. 17. An FDA study on consumer reactions to health claims was recently released (1"The Tan Sheet" Oct. 10, 2005, p. 7)...

You may also be interested in...

Qualified Claims Language And Grading Confuses Consumers – FDA Study

"Report card grade disclaimers" used to distinguish the amount of scientific evidence backing a health claim may cause consumers to be more skeptical of the science behind unqualified health claims compared to qualified claims, according an FDA survey

EMA To Address Problems With CTIS By Key January Deadline

The EU’s single-portal Clinical Trial Information System will become mandatory from 31 January 2023 for sponsors seeking clinical trial approval. Problems that some users have experienced while using the system voluntarily are being fixed, according to the European Medicines Agency.

Pharma Firms Must Act On Biodiversity Footprinting To Avoid Business Risks

Biodiversity footprinting may still be a new concept for pharmaceutical companies, but they need to put a clear supply chain strategy in place now, particularly as the COP 15 conference in December is expected to discuss mandatory reporting of biodiversity risks, says Luka Brown.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts